Validation of epigenetic biomarkers of head and neck cancer progression--OLD

描述(申请人提供)：头颈部鳞状细胞癌(HNSCC)是一种发病率和死亡率都很高的疾病，对预后、局部复发或存在癌前疾病没有可靠的指标。该项目专注于验证表观遗传的、基于启动子甲基化的唾液冲洗生物标记物，这些生物标记物以前已经开发并发表，使用了一组头颈部鳞状细胞癌(HNSCC)患者和未受影响的对照受试者。先前的数据表明，这些标记物对头颈部癌症的检测是特异的，初步数据显示，在HNSCC患者的治疗前唾液中检测这些标记物是局部复发和生存不良的独立预后指标。我们将1)在HNSCC患者唾液的单独验证队列中定义这些标记物，以确认与局部复发和总体存活率较低的相关性。我们还将2)分别在纽约大学牙科学院(U54DE014257，David Sirois博士)根据U54机制收集的恶性和癌前病变的临床口腔癌检测队列中验证和测试这些标记物。 公共卫生相关性：该项目专注于验证表观遗传学的、基于启动子甲基化的唾液冲洗生物标记物，这些生物标记物之前已经开发并发表，使用的是头颈部鳞状细胞癌(HNSCC)患者和未受影响的对照受试者的队列。

DESCRIPTION (provided by applicant): Head and Neck Squamous Cell Carcinoma (HNSCC) is a disease with significant morbidity and mortality, and without reliable indicators for prognosis, local recurrence, or presence of premalignant disease. This project is focused on validation of epigenetic, promoter methylation-based salivary rinse biomarkers that have been previously developed and published using a cohort of head and neck squamous cell carcinoma (HNSCC) patients and non-affected control subjects. Prior data shows these markers to be specific for head and neck cancer detection, and preliminary data show that detection of these markers in pretreatment salivary rinses in HNSCC patients is an independent prognostic indicator for local recurrence and poor survival. We will 1) define these markers in a separate validation cohort of salivary rinses from HNSCC patients to confirm association with local recurrence and poor overall survival. We will also 2) validate and test these markers in a clinical oral cancer detection cohort of malignant and premalignant lesions, respectively, previously collected under a U54 mechanism at the NYU College of Dentistry (U54DE014257, Dr. David Sirois). PUBLIC HEALTH RELEVANCE: This project is focused on validation of epigenetic, promoter methylation-based salivary rinse biomarkers that have been previously developed and published using a cohort of head and neck squamous cell carcinoma (HNSCC) patients and non-affected control subjects.